Pharm-Olam International Announces Expansion of Indian Operations

HOUSTON, TEXAS - Pharm-Olam International Ltd. (POI), a multi-national CRO to pharmaceutical, biotechnology and medical device industries, announces continued expansion of their Indian operations. The company's clinical staff has tripled since 2005 to meet sponsor demand for conducting trials in the country.

"Pharm-Olam is approaching our fourth year of helping sponsors conduct trials in India and we are excited about the potential for continued growth. India is a logical choice for larger studies of any indication due to rapid rates of recruitment, and lower investigator fees and treatment costs", said Iain Gordon, Director of Global Business Development. "India has a very high number of new oncology and infectious disease patients every year, resulting in greatly increased recruitment rates for treatment naïve patients."

Pharm-Olam International began operations in India opening an office in Bangalore in January 2003. Pharm-Olam can perform a free feasibility study with a sponsor's protocol at several of the largest centers in India to determine the actual incidence and patient availability within their large patient base. Sponsors can handle their Indian trial communications with Pharm-Olam corporate offices in the U.S. or U.K. avoiding problems with the differences in time zones.

Pharm-Olam conducts trials to the highest FDA and ICH/GCP standards, which are harmonious with Indian GCP standards. Interested sponsors can contact Pharm-Olam for a complimentary side by side comparison of ICH and Indian GCP standards.

For further information about Pharm-Olam India please contact Iain Gordon at igordon@pharm-olam.com.


About Pharm-Olam International

Pharm-Olam International is a multi-national contract research organization offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From pre-clinical to Phase IV, POI is focused on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines.